Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of ...

We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

For many of the almost 40 million people in the U.S. who live with diabetes, monitoring blood sugar levels multiple times a day can make the difference between good health and serious heart, kidney, ...

At the end of 2023, more than one-third of new prescriptions to treat Type 2 diabetes were GLP-1s, such as Mounjaro and Ozempic, among others, according to a study published April 15 in Annals of ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While ...